Genus jumps 11% as new Chinese pig JV formed at end of 'landmark' year

Genus PLC shares surged nearly 11% after reporting a 24% increase in annual adjusted profit before tax to £74.3 million, driven by robust growth across its porcine and bovine genetics divisions and strong cash generation. The livestock genetics group also announced a new joint venture with Beijing Capital Agribusiness (BCI) in China, which will provide Genus with $160 million in gross cash and future PRRS-resistant pig royalties, significantly bolstering its strategic expansion in the region following recent US FDA approval for its PRRS-resistant pigs. Analysts noted the strong financial delivery and the commercial acceleration from the China JV as key positives.

Analysis

Genus PLC has delivered a robust set of annual results, highlighted by a 24% increase in adjusted profit before tax to £74.3 million (38% at constant currency), which surpassed analyst expectations from Peel Hunt. This performance was driven by broad-based growth in its porcine (PIC) genetics business, which added 12 new royalty customers in China, and improved profitability in its bovine (ABS) division, with a further £6 million benefit expected. Critically, the company announced a new joint venture in China with Beijing Capital Agribusiness, which will provide an immediate $160 million in gross cash, accelerated milestone payments, and a pathway for future royalties from its proprietary PRRS-resistant pig (PRP) technology. This strategic deal significantly accelerates commercialization in a key market and follows the landmark US FDA approval for its PRP technology, a validation of its core innovation. The company's financial position has also strengthened, evidenced by £41 million in free cash inflow and a reduction in net debt to £228 million, all while maintaining its dividend at 32p per share.

Key Decisions for Investors

• The combination of a significant earnings beat, a cash-generative strategic JV in China, and major regulatory de-risking for its core PRP technology supports a bullish outlook on Genus.
• Investors should closely monitor the execution and revenue generation from the new Chinese joint venture and the timeline for further PRP regulatory approvals in other key global markets, as these are now the primary catalysts for future growth.
• While fundamentals are strong, the stock experienced significant volatility with a sharp initial rally; investors should evaluate the new valuation level in the context of the improved balance sheet and future royalty streams when considering position adjustments.